2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Shortness of Breath: new trials by email Literature Review of Shortness of Breath trials Research Report on Shortness of Breath
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) Hesperidin, Placebo - Covid19, Anosmia | Phase 2 | Completed | Montreal Heart Institute | 216 | 2021-02-18 | 2022-04-08 |
| Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol - Asthma, Bronchospasm | Phase 1 / Phase 2 | Completed | Amphastar Pharmaceuticals, Inc. | 23 | 2010-08-01 | 2017-07-25 |
Dyspnea (2) · Abdominal Pain (1) · Anosmia (1) · Arthralgia (1) · Asthma (1) · Bronchial Spasm (1) · COVID-19 (1) · Chest Pain (1) · Confusion (1) · Cough (1) · Fever (1) · Headache (1) · Muscle Weakness (1) · Myalgia (1) · Nausea (1)
Lung Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Signs and Symptoms (2) · Signs and Symptoms, Respiratory (2) · Body Temperature Changes (1) · Bronchial Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Infections (1) · Joint Diseases (1)
Epinephrine (1) · Hesperidin (1) · Inhalation (1)
Amphastar Pharmaceuticals, Inc. (1) · Montreal Heart Institute (1)
Canada (1) · United States (1)